Completed
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
NCT05256472
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China